- Home
- PRAX vs QRVO Comparison
PRAX vs QRVO Comparison
Compare PRAX & QRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | QRVO |
|---|---|---|
| Founded | 2015 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.1B |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | PRAX | QRVO |
|---|---|---|
| Price | $312.37 | $81.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 13 |
| Target Price | ★ $397.85 | $98.17 |
| AVG Volume (30 Days) | 623.7K | ★ 962.9K |
| Earning Date | 02-27-2026 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.30 |
| Revenue | $7,463,000.00 | ★ $3,663,072,000.00 |
| Revenue This Year | N/A | $3.36 |
| Revenue Next Year | $14,827.76 | $2.39 |
| P/E Ratio | ★ N/A | $34.75 |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $49.46 |
| 52 Week High | $326.91 | $106.30 |
Technical Indicators
Market Signals| Indicator | PRAX | QRVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 40.68 |
| Support Level | $266.93 | $78.82 |
| Resistance Level | $326.91 | $82.43 |
| Average True Range (ATR) | 17.87 | 2.48 |
| MACD | 0.13 | -0.32 |
| Stochastic Oscillator | 75.94 | 20.24 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.